Preserving Platelets for storage and transportation using a novel desiccation pro

使用新型干燥工艺保存血小板以进行储存和运输

基本信息

  • 批准号:
    8251061
  • 负责人:
  • 金额:
    $ 18.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-01 至 2012-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Although platelets are a critical component in hemostasis, current methods for platelet storage severely limit their utility as a lifesaving blood component. In related work conducted to date, we have developed methods to preserve mammalian cells in desiccated format for extended periods (> 6 months). The technology involves cell specific dehydration and rehydration buffering reagents coupled with vacuum assisted desiccation. A documented protocol for erythrocytes has been established and dried red cells are available in limited quantities for diagnostic applications (Hememics Biotech, MD). We have obtained preliminary data indicating the desiccation process developed can be applied to platelets. The desiccated platelets, upon rehydration, remain intact with overall size and function similar to that of in-dated platelets. Furthermore, when compared dried platelets that had gone through other drying techniques such as lyophilization, the desiccate platelets showed to be non-thrombogenic with very low micropartical content (a real concern for using platelets in transfusion medicine). In order to optimize the platelet desiccation process, in Phase I research, we propose to: 1) Desiccate platelets under various conditions by varying constituents of dehydration reagents, vacuum desiccation protocols, and storing samples in a dried format at room temperature for up to a month . 2) Determine the extent to which desiccated platelets recover functionality upon rehydration by performing tests to assess platelets physical and biological functions such as, size, activation status and thrombogenicity in our lab and the labs of our collaborators. Success in this endeavor will facilitate development of a standardized platelet desiccation protocol for therapeutic and diagnostic reagents with a goal to eliminate the need to discard outdated platelets (20% of all platelets) at a cost of ~ $400-$600 million annually to US health care system. The ability to stockpile dried platelets addresses a number of logistical issues by simplifying the delivery of life saving treatments in disaster areas, war zones and remote population centers. The endpoint of this phase I is to have sufficiently robust processes and protocols for the preservation of platelets to indicate potential for long term storage. We will propose further investigation and development in the Phase II SBIR project to establish protocols for dried stabilized platelets with long term preservation for general therapeutic and diagnostic applications. PUBLIC HEALTH RELEVANCE: The project proposes to use cell specific reagent and a vacuum assisted desiccation process to preserve platelets in dried state for long term preservation. The success of the project will extend the current shelf- life of platelets from 5-7 days to several months, making the cells available for therapeutic and diagnostic purposes.
描述(由申请人提供):虽然血小板是止血的关键成分,但目前的血小板储存方法严重限制了其作为救命血液的效用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David H Ho其他文献

David H Ho的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 18.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 18.55万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 18.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了